3D Medicines Inc. (Stock Code: 01244) published its monthly return for equity issuers, covering the period ended 28 February 2026. The company reported that its authorised share capital remained at 500 million ordinary shares, each with a par value of HKD 0.001, totaling HKD 500,000. No increase or decrease was recorded during the month.

The total number of issued shares remained unchanged at 258.18 million shares, and there were no treasury shares. The public float requirement of 25% was confirmed to be met as of the end of February 2026.

Regarding share options, 12.80 million share options remained outstanding under the existing scheme, with no new shares issued or transferred from treasury. No warrants, convertibles, or other arrangements to issue additional shares were reported. The company confirmed full compliance with Hong Kong listing rules in relation to these disclosures.